comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 21:07:09 - browse：673

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

WSS

UpToDate has a racism problem: Dr. Stanley Goldfarb

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO: Palliative care found as helpful given virtually as in person

Being 'nonadherent' patient made me a more empathetic doctor

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

The Pandemic Treaty must support building strong health systems

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

After affirmative action ruling, medical educators look to 'holistic review'

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Psychedelics group wrestles with new pharma identity

Beware reading your test results before your doctor does

Sports medicine is finally prioritizing gender equality

ASCO: AstraZeneca says CAR

Affirmative action in medical school literally saved lives

ASCO: AstraZeneca says CAR

At least 13 dead in Texas as scorching temps continue

Letters to First Opinion on caregivers, digital health, and more

hotspot

Fatty liver disease was alleviated by Lilly’s ‘triple

AstraZeneca lung cancer study comes in below expectations

Shifting the focus from loneliness to social health

ASCO: Palliative care found as helpful given virtually as in person

What affirmative action's end means to a medical student

Beware reading your test results before your doctor does

explore

leisure time

knowledge

focus